NewsBenzingaCAMP4 Therapeutics、CMP-002のグローバル第1/2相ASCEND臨床試験を欧州連合内の試験施設で開始するため、複数のEU加盟国の規制当局および倫理委員会からCTA承認を取得 CAMP4 Therapeutics、CMP-002のグローバル第1/2相ASCEND臨床試験を欧州連合内の試験施設で開始するため、複数のEU加盟国の規制当局および倫理委員会からCTA承認を取得 Benzinga 2026.10.27 12:06 (GMT+0) Open on Benzinga Other news AI models can be tricked into identifying civilians as military targets by telling them it’s a game Why Nvidia Is Falling Tuesday: Jensen Huang’s Comeback Statement, Congress Hearings, and AI Risks General Motors Plans 20% Boost In Robotics As Factory Costs Rise Eli Lilly Inks Multibillion-Dollar Pact to Develop Precision Cancer Therapies McKesson Stock Is a Triple Threat at New All-Time Highs. How to Trade It Here. 'Nvidia stopped disclosing Singapore sales as revenues hit $104B' -FT